Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results.

[1]  G. Tortora,et al.  Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  M. Baumann,et al.  Anti-VEGF Strategies in Combination with Radiotherapy , 2003 .

[3]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[4]  David H. Johnson.  Gefitinib (Iressa) trials in non-small cell lung cancer. , 2003, Lung cancer.

[5]  K. Nakashiro,et al.  Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer , 2003, International journal of cancer.

[6]  Torben Steiniche,et al.  The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. , 2004, International journal of radiation oncology, biology, physics.

[7]  Y. Yarden,et al.  Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Giaccone,et al.  Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Arteaga,et al.  Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[11]  P. Jayaprakash,et al.  Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix , 1998, Journal of Cancer Research and Clinical Oncology.

[12]  C. Davis,et al.  Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. , 1999, Cancer research.

[13]  R H Wheeler,et al.  Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Suit.  Modification of radiation response. , 1984, International journal of radiation oncology, biology, physics.

[15]  Localizing the EGF receptor , 2002, Nature Cell Biology.

[16]  N. Bander,et al.  Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  D. Hicklin,et al.  Epidermal growth factor receptor blockade by antibody IMC‐C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice , 2000, Cancer.

[18]  C. Langer,et al.  Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. , 2004, International journal of radiation oncology, biology, physics.

[19]  J. Hsuan,et al.  EGF receptors as transcription factors: ridiculous or sublime? , 2001, Nature Cell Biology.

[20]  M. Krause,et al.  Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse , 2003, International journal of radiation biology.

[21]  J. Grandis,et al.  Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. , 2004, Cancer treatment reviews.

[22]  M. Krause,et al.  Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice , 2003, International journal of radiation biology.

[23]  M. Krause,et al.  Impact of increased cell loss on the repopulation rate during fractionated irradiation in human FaDu squamous cell carcinoma growing in nude mice , 2003, International journal of radiation biology.

[24]  John Mendelsohn,et al.  The EGF receptor family as targets for cancer therapy , 2000, Oncogene.

[25]  Roy S Herbst,et al.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Giaccone,et al.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Kavanagh,et al.  Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation , 1997, Oncogene.

[28]  G. Steel,et al.  Basic Clinical Radiobiology , 1997 .

[29]  G. Giaccone,et al.  Ongoing and future trials of biologic therapies in lung cancer. , 2003, Lung cancer.

[30]  M. Berger,et al.  EGFR overexpression and radiation response in glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.

[31]  M. Fukuoka.  Final results from a phase II trial of ZD1839 ("Iressa") for patients with advanced non-small-cell lung cancer (IDEAL 1) , 2002 .

[32]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[33]  M. Kris,et al.  The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  B. Telfer,et al.  ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model , 2002, British Journal of Cancer.

[35]  M. Krause,et al.  Molecular targeting in radiotherapy of lung cancer. , 2004, Lung cancer.

[36]  Yosef Yarden,et al.  Signal transduction and oncogenesis by ErbB/HER receptors. , 2004, International journal of radiation oncology, biology, physics.

[37]  H. Modjtahedi,et al.  EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. , 1998, International journal of oncology.

[38]  R. Kallman.  Rodent tumor models in experimental cancer therapy , 1987 .

[39]  P. Harari,et al.  Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  N R Hunter,et al.  Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  M. Trivett,et al.  EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. , 2003, International journal of radiation oncology, biology, physics.

[42]  P. Harari,et al.  Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. , 1999, Cancer research.

[43]  M. Krause,et al.  Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. , 2001, International journal of radiation oncology, biology, physics.

[44]  H. Choy,et al.  Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. , 2003, Lung cancer.

[45]  P. Harari,et al.  Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). , 2002, Cancer research.

[46]  Tsung-Teh Wu,et al.  Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  M. Baumann,et al.  Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. , 1990, Radiation research.

[48]  G. Fontanini,et al.  Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  S. Briggs,et al.  Epidermal growth factor receptor-reactive monoclonal antibodies: xenograft antitumor activity alone and as drug immunoconjugates. , 1991, Cancer research.

[50]  Christopher U. Jones,et al.  Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J. Sham,et al.  Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[52]  J. Mendelsohn,et al.  Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. , 1984, Cancer research.

[53]  Roy S Herbst,et al.  Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.

[54]  K. Ang,et al.  In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  G. Giaccone,et al.  Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment , 2004 .

[56]  J. Baselga.  Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  K. Ang,et al.  C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. , 2001, International journal of radiation oncology, biology, physics.

[58]  W. Grizzle,et al.  Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. , 1999, Cancer biotherapy & radiopharmaceuticals.

[59]  M. Krause,et al.  Ultrafractionation in human malignant glioma xenografts , 2003, International journal of cancer.

[60]  J. Lett,et al.  Advances in Radiation Biology , 1976 .

[61]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  M. Krause,et al.  Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[63]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[64]  M. Sela,et al.  Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. , 1988, Journal of the National Cancer Institute.

[65]  D. Hicklin,et al.  Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. , 2002, International journal of radiation oncology, biology, physics.

[66]  R. Schmidt-Ullrich,et al.  Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. , 2001, International journal of radiation oncology, biology, physics.

[67]  R. Schmidt-Ullrich,et al.  Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. , 1996, Radiation research.

[68]  M. Krause,et al.  In regard to Solomon et al.: EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. IJROBP 2003;55:713-723. , 2003, International journal of radiation oncology, biology, physics.

[69]  H. Withers,et al.  Four R's of radiotherapy , 1975 .

[70]  K Kian Ang,et al.  Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? , 2004, Seminars in radiation oncology.